(Q35206367)

7 August 2017

1 reference

title

Monoclonal antibodies for the prevention and treatment of graft-versus-host disease (English)

1 reference

7 August 2017

1 reference

Rebecca J Bruner

1

1 reference

7 August 2017

Sherif S Farag

series ordinal

2

1 reference

7 August 2017

publication date

1 August 2003

1 reference

7 August 2017

1 reference

7 August 2017

volume

30

1 reference

7 August 2017

issue

4

1 reference

7 August 2017

page(s)

509-519

1 reference

Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Treatment of moderate and severe acute GVHD after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Acute graft-vs-host disease: pathobiology and management

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Advances in the treatment of graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Novel therapeutics for the treatment of graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Pathophysiologic mechanisms of acute graft-vs.-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

T-cell regulation by CD28 and CTLA-4.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Lymphocyte homing and homeostasis

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Transplantation of anergic histoincompatible bone marrow allografts

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

A phase I-II study evaluating the murine anti-IL-2 receptor antibody 2A3 for treatment of acute graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Prevention of graft versus host disease by inactivation of host antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

TNF-alpha targeted therapeutic approaches in patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Therapeutic effect of an anti-Fas ligand mAb on lethal graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Inhibition of graft-versus-host disease by interleukin-2 treatment is associated with altered cytokine production by expanded graft-versus-host-reactive CD4+ helper cells

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA-mismatched bone marrow transplant patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Graft-versus-host disease prevention by rapamycin: cellular mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

A toxicity study of trimetrexate used in combination with cyclosporine as acute graft-versus-host disease prophylaxis in HLA-mismatched, related donor bone marrow transplants.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent mu

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T-cell globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Anti-thymocyte-globulin as part of the preparative regimen prevents graft failure and severe graft versus host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO).

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Pretreatment of donor bone marrow with monoclonal antibody OKT3 for prevention of acute graft-versus-host disease in allogeneic histocompatible bone-marrow transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Failure of early administration of antithymocyte globulin to lessen graft-versus-host disease in human allogeneic marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

ATG plus corticosteroid therapy for acute graft-versus-host disease: predictors of response and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Combination therapy with tacrolimus and anti-thymocyte globulin for the treatment of steroid-resistant acute graft-versus-host disease developing during cyclosporine prophylaxis.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

A proposed objective way to assess results of randomized prospective clinical trials with acute graft-versus-host disease as an outcome of interest

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Use of antithymocyte globulin for treatment of steroid-refractory acute graft-versus-host disease: an international practice survey

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Mycophenolate mofetil for the prophylaxis of acute graft-versus-host disease in stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Mycophenolate Mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: four years of experience

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Etanercept in graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

T cell activation-associated epitopes of CD147 in regulation of the T cell response, and their definition by antibody affinity and antigen density

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

Cytokine dysregulation in chronic graft versus host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

How I treat chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900250-1

7 January 2021

10.1016/S0093-7754(03)00250-1

Identifiers

DOI

1 reference

7 August 2017

1 reference